Mirae Asset Global Investments’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$138M Buy
2,396,422
+476,894
+25% +$27.4M 0.2% 71
2026
Q1
$116M Sell
1,919,528
-195,832
-9% -$11.4M 0.04% 55
2025
Q4
$114M Sell
2,115,360
-96,485
-4% -$4.64M 0.32% 53
2025
Q3
$99.8M Buy
2,211,845
+93,528
+4% +$4.37M 0.31% 59
2025
Q2
$98.1M Buy
2,118,317
+454,160
+27% +$22.3M 0.34% 60
2025
Q1
$98.2M Buy
1,664,157
+97,997
+6% +$5.71M 0.4% 45
2024
Q4
$89.1M Buy
1,566,160
+172,439
+12% +$9.63M 0.36% 46
2024
Q3
$71M Buy
1,393,721
+147,246
+12% +$6.91M 0.31% 62
2024
Q2
$51.7M Buy
1,246,475
+68,723
+6% +$3.08M 0.26% 72
2024
Q1
$68.4M Buy
1,177,752
+763,213
+184% +$38.9M 0.15% 138
2023
Q4
$21.3M Sell
414,539
-48,525
-10% -$2.55M 0.04% 407
2023
Q3
$26.9M Buy
463,064
+13,562
+3% +$831K 0.06% 324
2023
Q2
$28.7M Sell
449,502
-118,575
-21% -$7.95M 0.06% 317
2023
Q1
$39.4M Buy
568,077
+42,095
+8% +$2.97M 0.09% 228
2022
Q4
$37.8M Buy
525,982
+38,827
+8% +$2.93M 0.1% 226
2022
Q3
$34.6M Buy
487,155
+48,572
+11% +$3.52M 0.09% 235
2022
Q2
$33.8M Buy
438,583
+70,167
+19% +$5.34M 0.09% 262
2022
Q1
$26.9M Buy
368,416
+3,300
+0.9% +$222K 0.06% 356
2021
Q4
$22.8M Buy
365,116
+66,890
+22% +$3.92M 0.05% 412
2021
Q3
$17.6M Buy
298,226
+44,067
+17% +$2.9M 0.04% 444
2021
Q2
$17M Buy
254,159
+33,972
+15% +$2.22M 0.05% 443
2021
Q1
$13.9M Sell
220,187
-94,905
-30% -$5.9M 0.05% 435
2020
Q4
$19.5M Buy
315,092
+36,007
+13% +$2.21M 0.07% 320
2020
Q3
$16.8M Buy
279,085
+15,000
+6% +$903K 0.08% 278
2020
Q2
$15.5M Sell
264,085
-36,327
-12% -$2.17M 0.09% 246
2020
Q1
$16.7M Buy
300,412
+48,057
+19% +$2.94M 0.13% 164
2019
Q4
$16.2M Buy
252,355
+22,570
+10% +$1.29M 0.1% 245
2019
Q3
$11.7M Buy
229,785
+24,984
+12% +$1.17M 0.08% 274
2019
Q2
$9.27M Buy
204,801
+18,109
+10% +$844K 0.06% 317
2019
Q1
$8.92M Sell
186,692
-25,273
-12% -$1.26M 0.07% 290
2018
Q4
$11M Sell
211,965
-25,779
-11% -$1.39M 0.1% 219
2018
Q3
$14.8M Buy
237,744
+58,445
+33% +$3.47M 0.11% 189
2018
Q2
$9.92M Buy
179,299
+3,959
+2% +$214K 0.13% 110
2018
Q1
$11.1M Buy
175,340
+18,028
+11% +$1.16M 0.15% 104
2017
Q4
$9.64M Buy
157,312
+8,193
+5% +$512K 0.13% 109
2017
Q3
$9.48M Buy
149,119
+12,695
+9% +$741K 0.17% 105
2017
Q2
$7.6M Buy
136,424
+8,482
+7% +$462K 0.13% 116
2017
Q1
$6.96M Sell
127,942
-2,029
-2% -$111K 0.13% 117
2016
Q4
$7.6M Buy
129,971
+44,501
+52% +$2.43M 0.17% 108
2016
Q3
$4.61M Sell
85,470
-143,102
-63% -$9.19M 0.1% 138
2016
Q2
$16.8M Buy
228,572
+4,665
+2% +$330K 0.43% 57
2016
Q1
$14.3M Sell
223,907
-23,811
-10% -$1.5M 0.39% 60
2015
Q4
$17M Sell
247,718
-2,359
-0.9% -$156K 0.56% 45
2015
Q3
$14.8M Buy
250,077
+1,997
+0.8% +$127K 0.61% 42
2015
Q2
$16.5M Sell
248,080
-31,458
-11% -$2.07M 0.53% 47
2015
Q1
$18M Buy
279,538
+5,721
+2% +$358K 0.61% 47
2014
Q4
$16.2M Sell
273,817
-90,746
-25% -$5.12M 0.59% 56
2014
Q3
$18.7M Sell
364,563
-238,763
-40% -$11.9M 0.67% 45
2014
Q2
$29.3M Sell
603,326
-9,200
-2% -$453K 0.65% 42
2014
Q1
$31.8M Buy
612,526
+581,800
+1,894% +$31M 0.81% 32
2013
Q4
$1.63M Buy
30,726
+674
+2% +$34.3K 0.07% 196
2013
Q3
$1.39M Buy
30,052
+190
+0.6% +$8.34K 0.06% 198
2013
Q2
$1.33M Buy
+29,862
New +$1.3M 0.07% 186

Other funds holding BMY

Mirae Asset Global Investments's BMY Position: Q2 2026 in Review

Mirae Asset Global Investments increased its Bristol-Myers Squibb (BMY) stake by 25% in Q2 2026, buying an estimated $27.4M and bringing the position to 2,396,422 shares worth $138M. The position accounts for 0.2% of the portfolio, ranked #71.

Mirae Asset Global Investments first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. 843 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Mirae Asset Global Investments held 2,396,422 shares of Bristol-Myers Squibb worth $138M as of Q2 2026.
  • Mirae Asset Global Investments bought 476,894 Bristol-Myers Squibb shares in Q2 2026, an estimated $27.4M.
  • Bristol-Myers Squibb made up 0.2% of Mirae Asset Global Investments's portfolio in Q2 2026, its #71 holding.
  • Mirae Asset Global Investments first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • 843 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.